tazemetostat,bvd-523
epizyme,eisai pharmaceutical
['match trial', 'tazemetostat']
results at #asco22 on #pediatricmatch trial arm c (apec1621c) - "tazemetostat in patients with tumors with alterations in ezh2 or the swi/snf complex", in poster discussion session, 12:30 - 2:00pm edt, on june 6th! learn more: 
Official Twitter account of the NCI Cancer Therapy Evaluation Program, providing updates to our trials research community. Privacy: https://t.co/47s9FxzVVe.